Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Intensity Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Intensity Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Dubin Thomas I H | Director | – | Jul 20, 2026 | 1 |
| Donovan Daniel | Director | – | Jul 20, 2026 | 1 |
| Goldberg Mark A | Director | – | Jul 20, 2026 | 1 |
| Leahy Emer | Director | – | Jul 20, 2026 | 1 |
| Wesolowski John M | Principal Accounting Officer | 7,102 | Jul 20, 2026 | 3 |
| Talamo Joseph | Chief Financial Officer | 2,239 | Jul 20, 2026 | 3 |
| Bender Lewis H | President and CEO | 118,549 | Jul 20, 2026 | 2 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.